[公告]中國再生醫學:第三季季度報告 2015/2016

[公告]中國再生醫學：第三季季度報告 2015/2016

時間：2016年03月15日 23:33:00&nbsp中財網

China Regenerative Medicine International Limited

中國再生醫學國際有限公司

Incorporated in the Cayman Islands with limited liability於開曼群島註冊成立之有限公司

Stock Code股份代號：8158

China Regenerative Medicine International Limited

中國再生醫學國際有限公司

Incorporated in the Cayman Islands with limited liability於開曼群島註冊成立之有限公司

Stock Code股份代號：8158

Third Quarterly Report 2015 / 2016第三季季度報告

CHARACTERISTICS OF THE GROWTH ENTERPRISE

MARKET (「GEM」) OF THE STOCK EXCHANGE OF

HONG KONG LIMITED (THE 「STOCK EXCHANGE」)

GEM has been positioned as a market designed

to accommodate companies to which a higher

investment risk may be attached than other

companies listed on the Stock Exchange.

Prospective investors should be aware of the

potential risks of investing in such companies and

should make the decision to invest only after due

and careful consideration. The greater risk profile

and other characteristics of GEM mean that it is

a market more suited to professional and other

sophisticated investors.

Given the emerging nature of companies listed on

GEM, there is a risk that securities traded on GEM

may be more susceptible to high market volatility

than securities traded on the Main Board and no

assurance is given that there will be a liquid market

in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the

Stock Exchange take no responsibility for the contents

of this report, make no representation as to its accuracy

or completeness and expressly disclaim any liability

whatsoever for any loss howsoever arising from or in

reliance upon the whole or any part of the contents of this

report.

This report, for which the directors of China Regenerative

Medicine International Limited (the 「Directors」) collectively

and individually accept full responsibility, includes

particulars given in compliance with the Rules Governing

the Listing of Securities on the GEM of the Stock

Exchange (the 「GEM Listing Rules」) for the purpose of

giving information with regard to China Regenerative

Medicine International Limited. The Directors, having

made all reasonable enquiries, confirm that to the best

of their knowledge and belief the information contained

in this report is accurate and complete in all material

respects and not misleading or deceptive, and there are

no other matters the omission of which would make any

statement herein or this report misleading.

香港聯合交易所有限公司（「聯交

所」）創業板（「創業板」）之特點

創業板之定位乃為相比其他在聯

交所上市之公司帶有較高投資風

險之公司提供一個上市之市場。

有意投資之人士應了解投資於

該等公司之潛在風險，並應經過

審慎周詳之考慮後方作出投資決

定。創業板之較高風險及其他特

色表示創業板較適合專業及其他

資深投資者。

鑑於在創業板上市之公司屬新興

性質，在創業板買賣之證券可能

會較在主板買賣之證券承受較大

之市場波動風險，同時無法保證

在創業板買賣之證券會有高流通

量之市場。

香港交易及結算所有限公司及聯

交所對本報告之內容概不負責，

對其準確性或完整性亦不發表任

何聲明，並明確表示概不就本報

告全部或任何部份內容而產生或

因依賴該等內容而引致之任何損

失承擔任何責任。

本報告旨在遵照聯交所創業板證

券上市規則（「創業板上市規則」）

之規定，提供有關中國再生醫學

國際有限公司之資料。中國再生

醫學國際有限公司各董事（「董

事」）對此共同及個別承擔全部

責任。董事在作出一切合理查詢

後確認，就彼等所深知及確信，

本報告所載資料在各重要方面均

屬準確完備，沒有誤導或欺詐成

分，且並無遺漏任何事項，足以

令致本報告或其所載任何陳述產

生誤導。

The board of Directors (the 「Board」) of China Regenerative 中國再生醫學國際有限公司（「本

Medicine International Limited (the 「Company」) hereby 公司」）董事會（「董事會」）謹此

announces the unaudited consolidated results of the 公佈本公司及其附屬公司（統稱

Company and its subsidiaries (collectively, the 「Group」) 「本集團」）截至二零一六年一月

for the three months and nine months ended 31 January 三十一日止三個月及九個月之未

2016, together with the comparative unaudited figures for 經審核綜合業績，連同二零一五

the corresponding period in 2015 as follows: 年同期之未經審核比較數字如下：

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND

OTHER COMPREHENSIVE INCOME

綜合損益及其他全面收入表

For the three months and nine months ended 31 January 2016

截至二零一六年一月三十一日止三個月及九個月

Three months ended Nine months ended

31 January 31 January

截至一月三十一日止截至一月三十一日止

三個月九個月

2016

二零一六年

2015

二零一五年

2016

二零一六年

2015

二零一五年

HK$』000

千港元

HK$』000

千港元

HK$』000

千港元

HK$』000

千港元

Notes

附註

Unaudited

未經審核

Unaudited

未經審核

Unaudited

未經審核

Unaudited

未經審核

Revenue收益

3 12,367 520 17,376 2,041

Cost of sales銷售成本

(3,454) (570) (5,247) (1,255)

Gross profit/(loss)毛利

╱（毛損）

8,913 (50) 12,129 786

Other income其他收入

35,244 439 98,548 794

Selling and administrative銷售及行政開支

expenses (98,765) (43,705) (228,296) (125,409)

Finance costs財務費用

4 (6,750) (778) (19,034) (2,353)

Loss before income tax除所得稅前虧損

5 (61,358) (44,094) (136,653) (126,182)

Income tax (expense)/credit所得稅（開支）

╱抵免

6 (5,968) 916 (2,459) 5,261

Loss for the period期內虧損

(67,326) (43,178) (139,112) (120,921)

Other comprehensive income其他全面收入

Items that may be reclassified其後可能重新分類

subsequently to profit or loss:至損益之項目：

Exchange (loss)/gain換算海外業務

on translation財務報表之滙兌

of financial statements（虧損）

╱收益

of foreign operations (20,149) (4,132) (28,181) 5,862

Total comprehensiveincome for the period

期內全面總收入

(87,475) (47,310) (167,293) (115,059)

China Regenerative Medicine International Limited Third Quarterly Report 2015/2016

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND

OTHER COMPREHENSIVE INCOME (Cont』d)

綜合損益及其他全面收入表（續）

For the three months and nine months ended 31 January 2016

截至二零一六年一月三十一日止三個月及九個月

Three months ended

31 January

截至一月三十一日止

三個月

Nine months ended

31 January

截至一月三十一日止

九個月

2016

二零一六年

2015

二零一五年

2016

二零一六年

2015

二零一五年

HK$』000

千港元

HK$』000

千港元

HK$』000

千港元

HK$』000

千港元

Notes

附註

Unaudited

未經審核

Unaudited

未經審核

Unaudited

未經審核

Unaudited

未經審核

(Loss)/profit for the period 以下人士應佔期內

attributable to:（虧損）

╱溢利：

Owners of the Company本公司擁有人

(67,796) (41,795) (135,602) (117,003)

Non-controlling interests非控股股東權益

470 (1,383) (3,510) (3,918)

(67,326) (43,178) (139,112) (120,921)

Total comprehensive income以下人士應佔全面

attributable to:總收入：

Owners of the Company本公司擁有人

(86,248) (45,296) (161,788) (110,864)

Non-controlling interests非控股股東權益

(1,227) (2,014) (5,505) (4,195)

(87,475) (47,310) (167,293) (115,059)

Loss per share for 本公司擁有人應佔

loss for the period 期內虧損之每股虧損

attributable to the owners

of the Company 8

— basic (HK cents) —基本（港仙）

(0.385) (0.351) (0.788) (0.988)

— diluted (HK cents) —攤薄（港仙）

N/A N/A N/A N/A

不適用不適用不適用不適用

2015/2016年第三季度業績報告中國再生醫學國際有限公司

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

綜合權益變動表

For the nine months ended 31 January 2016

截至二零一六年一月三十一日止九個月

Attributable to owners of the Company

本公司擁有人應佔

Noncontrolling

interests

非控股

股東權益

Total

合計

Share

Share Share Translation Special Other Option Accumulated

capital premium reserve reserve reserve reserve losses Sub-total

股本股份溢價換算儲備特殊儲備其他儲備購股權儲備累計虧損小計

HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000

千港元千港元千港元千港元千港元千港元千港元千港元千港元千港元

At 1 May 2014 (Audited)於二零一四年五月一日（經審核）

117,629 1,551,370 2,689 (200) (410,463) — (483,962) 777,063 2,987 780,050

Loss for the period期內虧損

— — — — — — (117,003) (117,003) (3,918) (120,921)

Other comprehensive income:其他全面收入：

Exchange gain/(loss) on translation 換算海外業務財務報表

of financial statements 之滙兌收益

╱（虧損）

of foreign operations — — 6,139 — — — — 6,139 (277) 5,862

Total comprehensive income 期內全面總收入

for the period — — 6,139 — — — (117,003) (110,864) (4,195) (115,059)

Shares issued at premium按溢價發行股份

1,500 37,500 — — — — — 39,000 — 39,000

Share issue expenses股份發行開支

— (134) — — — — — (134) — (134)

Capital contributions from 一間附屬公司之

non-controlling interests 非控股股東權益注資

of a subsidiary — — — — — — — — 27,785 27,785

At 31 January 2015 (Unaudited)於二零一五年一月三十一日

（未經審核）

119,129 1,588,736 8,828 (200) (410,463) — (600,965) 705,065 26,577 731,642

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

(Cont』d)

綜合權益變動表（續）

For the nine months ended 31 January 2016

截至二零一六年一月三十一日止九個月

Noncontrolling

interests Total

Attributable to owners of the Company非控股

本公司擁有人應佔股東權益合計

Share

Share Share Translation Special Other Option Accumulated

capital premium reserve reserve reserve reserve losses Sub-total

股本股份溢價換算儲備特殊儲備其他儲備購股權儲備累計虧損小計

HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000

千港元千港元千港元千港元千港元千港元千港元千港元千港元千港元

At 1 May 2015 (Audited)於二零一五年五月一日（經審核）

164,422 2,754,185 4,436 (200) (410,463) 24,678 (734,060) 1,802,998 41,217 1,844,215

Loss for the period期內虧損

— — — — — — (135,602) (135,602) (3,510) (139,112)

Other comprehensive income:其他全面收入：

Exchange loss on translation 換算海外業務財務報表

of financial statements 之滙兌虧損

of foreign operations — — (26,186) — — — — (26,186) (1,995) (28,181)

Total comprehensive income 期內全面總收入

for the period — — (26,186) — — — (135,602) (161,788) (5,505) (167,293)

Shares issued at premium按溢價發行股份

11,500 448,500 — — — — — 460,000 — 460,000

Issue of share options發行購股權

— — — — — 12,303 — 12,303 — 12,303

Acquisition of subsidiaries收購附屬公司

— — — — — — — —12,17312,173

Capital contributions from 一間附屬公司之

non-controlling interests 非控股股東權益注資

of a subsidiary — — — — — — — —3,2973,297

Share issue expenses股份發行開支

— (3,894) — — — — — (3,894) — (3,894)

At 31 January 2016 (Unaudited)於二零一六年一月三十一日

（未經審核）

175,922 3,198,791 (21,750) (200) (410,463) 36,981 (869,662) 2,109,619 51,182 2,160,801

The special reserve represents the difference between the

nominal value of the shares of the acquired subsidiaries

and the nominal value of the Company’s share issued for

their acquisition at the time of the Group’s reorganization

in 2001.

The other reserve represents the difference between

the fair value of consideration paid to increase the

shareholding in a subsidiary, Shaanxi Aierfu Activtissue

Engineering Company Limited, and the amount of

adjustment to non-controlling interests during the years

ended 30 April 2011, 2013 and 2014.

特殊儲備指本集團於二零零一年

重組時，被收購附屬公司股份面

值與本公司就收購該等附屬公司

而予以發行之本公司股份面值之

差額。

其他儲備指於截至二零一一年、

二零一三年及二零一四年四月

三十日止年度就增加於一間附屬

公司（陝西艾爾膚組織工程有限公

司）之股權所付代價之公平值與非

控股股東權益調整金額之差額。

1. GENERAL INFORMATION 1.一般資料

China Regenerative Medicine International Limited (the 中國再生醫學國際有限公司

「Company」) was incorporated as an exempted company （「本公司」）於二零零一年四月

with limited liability in the Cayman Islands under the 二十日根據開曼群島公司法（二

Companies Law (Revision 2001) of Cayman Islands on 零零一年修訂版）在開曼群島

20 April 2001. The address of its registered office is P.O. 註冊成立為獲豁免有限公司。

Box 309, Ugland House, Grand Cayman, KY1-1104, 其註冊辦事處及主要營業地點

Cayman Islands and its principal place of business is 10th 之地址分別為

P.O. Box 309,

Floor, Dah Sing Financial Centre, 108 Gloucester Road, Ugland House, Grand Cayman,

Wanchai, Hong Kong. The Company’s shares are listed KY1-1104, Cayman Islands及

on the Growth Enterprises Market (「GEM」) of the Stock 香港灣仔告士打道

108號大新

Exchange of Hong Kong Limited (the 「Stock Exchange」). 金融中心

10樓。本公司股份於

香港聯合交易所有限公司（「聯

交所」）創業板（「創業板」）上

市。

The Company is an investment holding company. The 本公司為一間投資控股公司，

principal activities of its subsidiaries are engaged in 其附屬公司的主要業務為從事

research and development of bio-medical and healthcare 生物醫學產品和醫療保健產品

products, and medical techniques; the provision of the 及醫療技術之研發；提供組織

production and sales of tissue engineering products and 工程產品及其相關副產品的生

its related by-products; as well as sales and distribution of 產及銷售；以及銷售及分銷醫

medical products and equipment. 療產品及設備。

2. BASIS OF PREPARATION 2.編製基準

The unaudited consolidated results for the nine 截至二零一六年一月三十一日

months ended 31 January 2016 have been prepared 止九個月的未經審核綜合業績

in accordance with the Hong Kong Financial Reporting 乃遵照香港會計師公會頒佈之

Standards (「HKFRSs」, which also include the Hong 香港財務報告準則（「香港財務

Kong Accounting Standard (「HKAS」) and Interpretations) 報告準則」，亦包括香港會計

issued by the Hong Kong Institute of Certified Public 準則（「香港會計準則」）及詮

Accountants, and with applicable disclosure requirements 釋），以及創業板證券上市規則

of the Rules Governing The Listing of Securities on the 及香港公司條例之適用披露規

GEM and the Hong Kong Companies Ordinance. 定所編製。

The unaudited consolidated results do not include all the 本未經審核綜合業績並無載有

information and disclosures required in the annual financial 年度財務報表所規定的所有資

statements, and should be read in conjunction with the 料及披露事項，應與本集團截

annual financial statements of the Group for the year 至二零一五年四月三十日止年

ended 30 April 2015. The accounting policies and basis 度之年度財務報表一併閱讀。

of preparation adopted in the preparation of the unaudited 除採納多項經修訂香港財務報

consolidated results are the same as those used in the 告準則（於二零一五年五月一日

Group’s annual financial statements for the year ended 開始之財政年度生效）之影響

30 April 2015 except for the impact of the adoption of a 外，編製本未經審核綜合業績

number of revised HKFRSs, which are effective for the 所採納之會計政策及編製基準

financial year beginning on 1 May 2015. The adoption 與本集團截至二零一五年四月

of these new HKFRSs had no material effect on the 三十日止年度之年度財務報表

results of the Group for the current or prior accounting 所採納者相一致。採納該等新

periods. Accordingly, no prior period adjustment has been 訂香港財務報告準則對本集團

recognised. 當前或過往會計期間之業績並

無重大影響，故並無確認過往

期間調整。

2. BASIS OF PREPARATION (Cont』d) 2.編製基準（續）

The Group has not early applied new and revised HKFRSs

that have been issued but are not yet effective. The

Directors anticipate that the application of the new and

revised HKFRSs will have no material impact on the results

and financial position of the Group.

本集團並無提前應用已頒佈但

尚未生效之新訂及經修訂香港

財務報告準則。董事預期，應

用新訂及經修訂香港財務報告

準則將不會對本集團之業績及

財務狀況構成重大影響。

The unaudited consolidated results have been reviewed

by the Audit Committee of the Company.

本未經審核綜合業績已由本公

司審核委員會審閱。

3. REVENUE 3.收益

The Group’s turnover which represents revenue from its

principal activities, measured at the net invoiced value

of goods sold, after allowances for returns and trade

discounts during the periods are as follows:

本集團之營業額（指於來自期內

之主要活動，按扣除退貨及貿

易折扣後之已售貨品發票淨值

計算之收益）呈列如下：

Nine months ended 31 January

截至一月三十一日止九個月

2016 2015

二零一六年二零一五年

HK$』000 HK$』000

千港元千港元

Unaudited Unaudited

未經審核未經審核

Sale of tissue engineering組織工程產品銷售

products 4,790 1,546

Sale of stem cell products 幹細胞產品銷售18 —

Sale of cosmetic and 美容及保健產品銷售10,694 —

health products

Sale of medical products醫療產品及設備銷售

and equipment 1,874 495

17,376 2,041

4. FINANCE COSTS 4.財務費用

Nine months ended 31 January

截至一月三十一日止九個月

2016 2015

二零一六年二零一五年

HK$』000 HK$』000

千港元千港元

Unaudited Unaudited

未經審核未經審核

Interest on bank borrowings and須於一年內全部償還之

other payables wholly 銀行借款及其他應付

repayable within one year賬項之利息19,034 2,353

2015/2016年第三季度業績報告中國再生醫學國際有限公司

5. LOSS BEFORE INCOME TAX 5.除所得稅前虧損

Nine months ended 31 January

截至一月三十一日止九個月

2016 2015

二零一六年二零一五年

HK$』000 HK$』000

千港元千港元

Unaudited Unaudited

未經審核未經審核

Loss before income tax has除所得稅前虧損已

been arrived at after扣除╱（計入）

charging/(crediting):下列各項：

Amortisation of land use rights土地使用權攤銷82 84

Amortisation of other intangible其他無形資產攤銷

assets, included in cost of sales （已包括在銷售成本及

and administrative expenses行政開支中）28,927 27,670

Bad debt expense壞賬開支22 —

Depreciation折舊9,721 4,661

Equity-settled share-based支付予第三方顧問1,884 —

payments to third party 以權益結算

consultants之股權支付費用

Exchange difference, net滙兌差額（淨額）31,810 1,108

Loss on disposal of subsidiaries出售附屬公司之虧損30 —

Operating lease rentals辦公室物業之經營租賃

in respect of office premises租金18,196 14,352

Research and development costs 研發成本（附註(i)）36,982 27,247

(note (i))

Less: Capitalisation to other減：資本化至其他無形

intangible assets資產(3,386) (6,210)

33,596 21,037

Employee benefit expenses僱員福利開支

(including directors』（包括董事酬金）：

emoluments):

Salaries, wages and薪金、工資及其他福利

other benefits 53,784 33,515

Equity-settled share-based 以權益結算之股權

payments支付費用10,419 —

Retirement benefit scheme退休福利計劃供款

contributions 7,363 3,676

Interest income利息收入(62,180) (429)

China Regenerative Medicine International Limited Third Quarterly Report 2015/2016

5.

LOSS BEFORE INCOME TAX (Cont』d)

(i)

Research and development costs included

amortisation of other intangible assets, depreciation

and staff costs for employees in Research and

Development Department, which are also included

in the amount disclosed separately above.

6.

INCOME TAX EXPENSE/(CREDIT)

5.

除所得稅前虧損（續）

(i)研發成本包括研發部其

他無形資產攤銷、折舊

及僱員的員工成本，亦

已計入上表單獨披露的

金額內。

6.

所得稅開支╱（抵免）

Nine months ended 31 January

截至一月三十一日止九個月

2016 2015

二零一六年二零一五年

HK$』000 HK$』000

千港元千港元

Unaudited Unaudited

未經審核未經審核

Profits Tax — for the period利得稅—期內

Hong Kong香港— —

The PRC中國7,565 —

Deferred taxation遞延稅項(5,106) (5,261)

Total income tax expense/(credit)總所得稅開支╱（抵免）2,459 (5,261)

No Hong Kong Profits Tax has been provided in the

unaudited consolidated result for the nine months ended

31 January 2016 as the Group had no assessable profits

(2015: Nil).

Income tax on profits arising outside Hong Kong has been

calculated on the estimated assessable profits for the

period at the rates of income tax prevailing in the countries

in which the Group operates.

由於本集團並無應課稅溢利，

故截至二零一六年一月三十一

日止九個月之未經審核綜合業

績並無計提任何香港利得稅（二

零一五年：無）。

香港以外地區溢利之所得稅乃

根據期內估計應課稅溢利，按

本集團經營所在地之現行所得

稅率計算。

2015/2016年第三季度業績報告中國再生醫學國際有限公司

China Regenerative Medicine International Limited Third Quarterly Report 2015/2016 10

7. DIVIDENDS

The Board does not recommend the payment of dividend

for the nine months ended 31 January 2016 (2015: Nil).

8. LOSS PER SHARE

The calculation of the basic and diluted loss per share

attributable to owners of the Company is based on the

following data:

Unaudited未經審核Three months ended Nine months ended

31 January 31 January

截至一月三十一日截至一月三十一日

止三個月止九個月

2016 2015 2016 2015

二零一六年二零一五年二零一六年二零一五年

HK$』000 HK$』000 HK$』000 HK$』000

千港元千港元千港元千港元

Loss for the period attributable 用以計算每股基本虧損

to owners of the Company 之本公司擁有人應佔

for the purpose of basic loss 期內虧損

per share 67,796 41,795 135,602 117,003

Number of shares:股份數目：』000 』000 』000 』000

千股千股千股千股

Weighted average number 用以計算每股基本虧損

of ordinary shares for 之普通股加權平均數

the purpose of basic loss

per share 17,592,180 11,912,880 17,217,180 11,837,880

For the nine months ended 31 January 2016, diluted loss

per share attributable to owners of the Company was not

presented because the impact of the exercise of share

options was anti-dilutive.

Diluted loss per share for the period ended 31 January

2015 was not presented as there were no potential

ordinary shares in issue during the respective periods.

7.股息

董事會並不建議派付截至二零

一六年一月三十一日止九個月

之股息（二零一五年：無）。

8.每股虧損

本公司擁有人應佔每股基本及

攤薄虧損乃根據以下資料計算：

截至二零一六年一月三十一日

止九個月，由於行使購股權具

反攤薄影響，故並無呈列有關

本公司擁有人應佔每股攤薄虧

損。

由於相關期內並無任何已發行

潛在普通股，故並無呈列有關

截至二零一五年一月三十一日

止期間之每股攤薄虧損。

China Regenerative Medicine International Limited Third Quarterly Report 2015/2016 10

7. DIVIDENDS

The Board does not recommend the payment of dividend

for the nine months ended 31 January 2016 (2015: Nil).

8. LOSS PER SHARE

The calculation of the basic and diluted loss per share

attributable to owners of the Company is based on the

following data:

Unaudited未經審核Three months ended Nine months ended

31 January 31 January

截至一月三十一日截至一月三十一日

止三個月止九個月

2016 2015 2016 2015

二零一六年二零一五年二零一六年二零一五年

HK$』000 HK$』000 HK$』000 HK$』000

千港元千港元千港元千港元

Loss for the period attributable 用以計算每股基本虧損

to owners of the Company 之本公司擁有人應佔

for the purpose of basic loss 期內虧損

per share 67,796 41,795 135,602 117,003

Number of shares:股份數目：』000 』000 』000 』000

千股千股千股千股

Weighted average number 用以計算每股基本虧損

of ordinary shares for 之普通股加權平均數

the purpose of basic loss

per share 17,592,180 11,912,880 17,217,180 11,837,880

For the nine months ended 31 January 2016, diluted loss

per share attributable to owners of the Company was not

presented because the impact of the exercise of share

options was anti-dilutive.

Diluted loss per share for the period ended 31 January

2015 was not presented as there were no potential

ordinary shares in issue during the respective periods.

7.股息

董事會並不建議派付截至二零

一六年一月三十一日止九個月

之股息（二零一五年：無）。

8.每股虧損

本公司擁有人應佔每股基本及

攤薄虧損乃根據以下資料計算：

截至二零一六年一月三十一日

止九個月，由於行使購股權具

反攤薄影響，故並無呈列有關

本公司擁有人應佔每股攤薄虧

損。

由於相關期內並無任何已發行

潛在普通股，故並無呈列有關

截至二零一五年一月三十一日

止期間之每股攤薄虧損。

9. OPERATING LEASE COMMITMENTS 9.經營租賃承擔

AS LESSEE 作為承租方

The Group leases a number of properties under operating 本集團根據經營租賃租用若干

leases. The leases run for an initial period of one to five 物業。有關租約初始期為一至

years. None of the leases include contingent rentals. 五年。此等租約概無包括或有

租金。

At the reporting date, the total future minimum lease 於報告日期，根據不可撤銷經

payments under non-cancellable operating leases are as 營租賃而須支付之未來最低租

follows: 金總額如下：

31 January 30 April

2016 2015

二零一六年二零一五年

一月三十一日四月三十日

HK$』000 HK$』000

千港元千港元

Unaudited Audited

未經審核經審核

Within one year一年內22,244 17,864

In the second to fifth第二至第五年

year inclusive（包括首尾兩年）23,784 13,470

46,028 31,334

10. CAPITAL AND OTHER COMMITMENTS 10.資本及其他承擔

As at 31 January 2016, the Group had capital and other 於二零一六年一月三十一日，

commitments as follows: 本集團之資本及其他承擔如下：

31 January 30 April

2016 2015

二零一六年二零一五年

一月三十一日四月三十日

HK$』000 HK$』000

千港元千港元

Unaudited Audited

未經審核經審核

Contracted but not provided for:已訂約但未撥備：

Purchase of property,購置物業、廠房

plant and equipment及設備4,501 —

Authorised but not contracted for:已授權但未訂約：

Purchase of property, plant購置物業、廠房及設備

and equipment 89,305 —

2015/2016年第三季度業績報告中國再生醫學國際有限公司

10. CAPITAL AND OTHER COMMITMENTS 10.資本及其他承擔（續）

(Cont』d)

The Company signed two sponsorship agreements with 本公司與牛津大學就幹細胞治

the University of Oxford on the research of stem cell 療及組織工程的研究訂立兩份

therapy and tissue engineering. The Company agreed to 贊助協議。本公司同意於協

pay GBP9,000,000 (equivalent to HK$99,720,000) to the 議涵蓋期間向牛津大學分期

University of Oxford by instalments over the period covered 支付

9,000,000英鎊（相當於

by the agreements. Up to 31 January 2016, the Company 99,720,000港元）。截至二零

has paid GBP2,250,000 (equivalent to HK$26,572,000) (up 一六年一月三十一日，本公司

to 30 April 2015: has paid GBP1,500,000 (equivalent to 已向牛津大學支付

2,250,000HK$18,250,000)) to the University of Oxford. 英鎊（相當於

26,572,000港元）

（截至二零一五年四月三十日：

已支付

1,500,000英鎊（相當於

18,250,000港元）

））。

On 9 January 2015, the Group entered into a sale 於二零一五年一月九日，本集

and purchase agreement with Remed Tiger Limited 團與

Remed Tiger Limited（「賣

(the「Vendor」), a company beneficially wholly-owned by 方」，一間由崔佔峰院士實益全

Professor Zhanfeng Cui and a third party independent of 資擁有的公司，並為獨立於本

and not connected with the Company and its connected 公司及其關連人士且與彼等概

persons, to acquire up to 82.353% equity interest of 無關連的第三方）訂立一份買賣

Frame Sharp Limited, which effectively represents 70% 協議，以

42,500,000港元代價

equity interest of 奧凱（蘇州）生物技術有限公司, at a 收購

Frame Sharp Limited最多

consideration of HK$42,500,000 (「AK Acquisition」). 82.353%股權（實際相當於奧凱

Details of AK Acquisition were disclosed in the Company’s （蘇州）生物技術有限公司

70%

announcement dated 9 January 2015. The acquisition 股權）（「奧凱收購事項」）。奧凱

was completed on 14 August 2015. 收購事項之詳情披露於本公司

日期為二零一五年一月九日之

公告內。此收購已於二零一五

年八月十四日完成。

MANAGEMENT DISCUSSION

AND ANALYSIS

The Group continues to commit to our R&Ds and

commercialisation in four major areas of businesses,

namely tissue engineering; cellular and stem cell therapy;

cosmetic and healthcare; as well as medical equipment

and other services. In August 2015, the Group completed

the acquisition of 70.0% of equity interest of Frame Sharp

Limited, which effectively represents 70.0% of equity

interest of 奧凱（蘇州）生物技術有限公司 (AK (Suzhou)

Biomedical Ltd., 「AK Suzhou」) through contractual

arrangements. AK Suzhou focuses on providing services

in relation to clinical-grade human autologous cells

and stem cell isolation, purification, expansion and

cryopreservation. As part of the expansion program in

regenerative medicine and the reason that cell and stem

cell processing requires regional presence, this acquisition

will provide the Group with an opportunity to setup a

regional hub as the complimentary regional coverage

that takes care of human cell and stem cell processing

businesses in the Huadong Region (Eastern China

Region).

Upon completion of the acquisition of AK Suzhou, the

Group now has five production plants with two located

in Xian, Shaanxi Province; one located in Shenzhen,

Guangdong Province; one in Suzhou, Jiangsu Province;

one in Tianjin Municipality. These existing plants are

strategically located to capture most of the better

developed cities in the PRC so as to facilitate the Group's

commercialisation of our existing and future products and

services.

In October 2015, the Group jointly entered into a

memorandum of understanding (「MOU」), during the State

Visit to the United Kingdom by President Xi Jinping of the

PRC, to establish the 「The CCBI-CRMI Technology Centre

at the University of Oxford」 with the University of Oxford

and CCB International (Holdings) Limited, a wholly-owned

subsidiary of China Construction Bank Corporation. This

was one of the cooperation achievements for life sciences

recognized during the State Visit to the United Kingdom

by President Xi.

Being a high-tech pioneer company in regenerative

medicine industry, the Group continues to develop and

enrich our tissue-engineering operations and unremittingly

to explore viable opportunities along the value-chain of

cell and stem cell related businesses.

管理層討論及分析

本集團繼續致力於四個主要業務

領域（即組織工程；細胞及幹細胞

療法；美容及保健；以及醫療設

備及其他服務）之研發以及商業

化。於二零一五年八月，透過合

約安排，本集團完成收購

Frame

Sharp Limited的

70.0%股權，即

實際相等於奧凱（蘇州）生物技術

有限公司（「奧凱蘇州」）的

70.0%

股權。奧凱蘇州專注於提供有關

臨床應用級別的人體自體細胞及

幹細胞分離、純化、擴增及凍存

之服務。作為再生醫學擴充項目

的一部分以及考慮到細胞和幹細

胞處理具地域性要求，此收購項

目將為本集團提供機會於華東地

區（中國東部地區）建立區域中

樞，以補充地域覆蓋，處理人體

細胞及幹細胞業務。

繼完成收購奧凱蘇州後，本集團

目前擁有五個生產基地，其中兩

個位於陝西省西安市，一個位於

廣東省深圳市；一個位於江蘇省

蘇州市；一個位於天津市。該等

現有的生產基地均策略性地選址

於中國較發達的城市，以配合本

集團現有及未來產品及服務之商

業化。

於二零一五年十月，在中國國家

主席習近平在英國進行國事訪問

期間，本集團與牛津大學以及中

國建設銀行之全資附屬公司建銀

國際（控股）有限公司共同訂立諒

解備忘錄（「諒解備忘錄」），以籌

建「建銀國際

·中國再生醫學牛津

大學技術研發中心」。這被視為是

習主席對英國進行國事訪問期間

中英之間生命科學的合作成果之

一。

作為再生醫學行業的高科技先驅

企業，本集團繼續致力發展和豐

富我們的組織工程業務，同時不

斷開拓細胞及幹細胞相關業務價

值鏈上的可行商機。

OPERATIONS REVIEW

A) TISSUE ENGINEERING

Tissue Engineered Skin with Living

Human Cells — ActivSkin.

ActivSkin. is a tissue-engineered skin and it is the

first registered product of the Group. It can relieve

pains, shorten healing time and reduce scarring for

treating burns and scalds.

We have commenced sales of ActivSkin. in small

quantity which have been transplanted onto

patients. Some hospitals have used ActivSkin.

on patients gradually, while some doctors

are performing trial uses on clinical efficacy.

Negotiations with various hospitals are still

underway. Initially, we prefer to sell relatively small

quantity per order because ActivSkin. demands

special logistic arrangement to ensure clinical

efficacy.

We have committed to serve victims of accidents

or natural catastrophes by means of sponsorships

and donations since 2014. In December 2015, we

committed to donate ActivSkin. to the burn victims

in Yinchuan explosions. The Group will continue to

take an active role in sharing social responsibilities,

helping the needy and caring for our community.

Acellular Corneal Stroma — 「Acornea」

Our acellular corneal stroma, Acornea, was

approved by the China Food and Drug

Administration (「CFDA」) and its registration

certificate for medical device (「Product Certificate」)

has been obtained in April 2015.

業務回顧

A)組織工程

人體活細胞組織工程皮

膚

—安體膚

.

安體膚

.是一種組織工程皮

膚，為本集團首個註冊產

品。其在治療燒傷和燙傷方

面可以有效地減輕病患者疼

痛，縮短癒合時間，並減少

疤痕。

我們已開始銷售少量安體膚

.

並已移植於病者身上。一些

醫院已逐漸在患者身上應用

安體膚

.，而一些醫生正在

試用安體膚

.以驗證臨床療

效。目前與多間醫院的洽談

仍在進行中。由於安體膚

.

需要特殊的物流安排來確保

臨床療效，我們傾向於在初

始階段按單小量銷售。

自二零一四年起，我們通過

資助和捐贈的方式，致力向

意外事故或自然災害的受害

者給予幫助。於二零一五年

十二月，我們承諾向銀川爆

炸事件中被燒傷的受害者捐

贈安體膚

.。本集團將繼續

積極承擔社會責任，向需要

幫助的人士施以援手並關愛

我們的社區。

脫細胞角膜基質

—「艾

欣瞳」

我們的脫細胞角膜基質「艾

欣瞳」已獲得國家食品藥

品監督管理總局（「藥監總

局」）的批准，並於二零一五

年四月獲得醫療器械註冊證

（「產品註冊證書」）。

The Group has entered into respective

distribution agreements and relevant schedule

agreements (collectively referred to as 「Distribution

Agreements」) with a cumulative total of 26

provincial distributors, who are independent third

parties, to develop the sale of the Group’s Acornea.

Since then, there have been more than 100 pieces

of Acornea sold.

Since May 2015, the Group has formed an

ophthalmology expert committee with key opinion

leaders from various leading hospitals to provide

surgical technique training for junior ophthalmic

surgeons to better understand the applications of

Acornea. This training will cater for more suitable

ophthalmologists, thus allowing the applications

to be widely and extensively used in therapeutic

lamellar keratoplasty and paving possible future

product upgrades and development.

Since November 2015, the Group has established a

」CRMI clinician training institute」「中國再生醫學臨

床醫師培訓學院」

(the 「Institute」) in Beijing, aiming

at providing training course for cornea transplant

surgeries. The Institute provides a platform for

experienced corneal transplant surgeons to

enhance their theoretical knowledge and handson

experience on lamellar keratoplasty, as well

as their understanding on the characteristics and

applications of Acornea. Together with the training

courses to be held in Shandong Ophthalmology

Hospital, we target to train around a thousand

ophthalmologists in three years.

Up to February 2016, we completed ten training

courses in Shandong and Beijing for cornea

transplant of which over one hundred fifty junior

ophthalmic surgeons from various provinces

received training on both surgical principles

and practical workshop. Their cornea surgical

technique is believed to be improved with handson

experience on lamellar keratoplasty.

本集團已與累計合共二十六

家省級分銷商（均為獨立第

三方），分別訂立經銷協議

及相關附錄協議（統稱為

「經銷合作協議」），以拓展

本集團的艾欣瞳銷售。其

後，本集團已售出逾

100個

艾欣瞳。

本集團自二零一五年五月以

來，成立由不同領先醫院的

關鍵意見領袖組成的眼科專

家委員會，為資歷較淺的眼

科醫生提供手術技術培訓，

增進彼等對艾欣瞳應用的了

解。該培訓將面向更多合適

的眼科醫生提供，以使艾欣

瞳更普遍及廣泛地應用於治

療性板層角膜移植術，以及

為未來產品升級及開發作準

備。

自二零一五年十一月以來，

本集團在北京成立「中國再

生醫學臨床醫師培訓學院」

（「學院」），旨在提供角膜移

植手術培訓課程。學院為有

經驗的角膜移植醫生提供了

一個平臺，使彼等可以提高

有關板層角膜移植術理論知

識、積累實踐經驗並增進對

艾欣瞳的特點及應用的理

解。加上將於山東省眼科醫

院進行的培訓課程，我們計

劃於三年內培訓約一千名眼

科醫生。

截至二零一六年二月，我們

已於山東及北京完成十個角

膜移植的培訓課程，來自不

同省份的一百五十餘名初級

眼科醫生接受了手術原理和

實踐培訓。相信彼等的角膜

外科技術會在板層角膜移植

術實踐經驗中逐步提升。

The Group is committed to help address the

cornea shortage in China by taking initiatives to

donate our bio-engineered cornea to charitable

organisations in Shandong, Guizhou, Jiangxi,

Shaanxi and Gansu. The Group will continue to

exercise our commitments by giving supports to

charities or community projects, in particular to

deprived areas, and offering the underprivileged

who suffer from cornea related disease with an

opportunity to restore their vision.

Calcined Bovine Bone — 「Gegreen」

Gegreen is a protein-detracted bone substitute

material for inducing natural bone regeneration.

It is intended to be used by dental professionals

for the application of jawbone defect restoration,

particularly in dental implantation and treatment of

periodontal defects.

The production of Gegreen is under the

management of our subsidiary, Shaanxi Reshine

Biotech Co., Ltd (「Reshine」). In early 2015,

Reshine had to look for a new place to house its

production facilities due mainly to the previous

landlord's building planning adjustment. Reshine

then found a new suitable place at the northeastern

corner of Xian for its relocation. Recently, the

new plant completed its fit-outs and all facilities

and equipment had been installed and validated.

Production has resumed since January 2016.

Acellular Anal Fistula Repair Stroma —

「Asiunin」 (formerly known as Acellular

Small Intestinal Submucosa, namely

Resunin)

The Group has obtained the Product Certificate of

Asiunin in October 2015. Similar to Gegreen, the

Product Certificate of Asiunin has been successfully

updated with the new factory address. The Group

has commenced the commercialisation of Asiunin

and starts to negotiate with potential distributors

for provincial dealership.

本集團致力協助解決中國角

膜短缺的問題，主動向山東

省、貴州省、江西省、陝西

省及甘肅省慈善組織捐贈我

們的生物工程角膜。本集團

將繼續踐行我們的承諾，為

慈善機構或社區項目，尤其

是貧困地區提供支持，以及

為罹患角膜相關疾病的弱勢

社群提供恢復視力的機會。

天然煅燒骨修復材料

—

「骼瑞」

骼瑞是一種可引導天然骨再

生的脫蛋白質骨替代材料，

被牙科專業人士應用於頜骨

缺損修復，特別是用於牙科

種植及牙周骨缺損的治療。

骼瑞之生產是由我們的附屬

公司陝西瑞盛生物科技有限

公司（「瑞盛」）管理。於二

零一五年初，主要由於前業

主調整樓宇規劃，瑞盛需尋

求新地點以存置其生產設

施。瑞盛其後於西安東北區

找到一處合適的搬遷新址。

目前新廠房已完成裝修且所

有設施及設備已安裝調試完

畢。生產已於二零一六年一

月起恢復。

脫細胞肛瘻修復基質

—

「瑞栓寧」（前稱脫細胞粘

膜基質，名為瑞栓寧）

本集團已於二零一五年十月

獲得瑞栓寧之產品註冊證

書。與骼瑞類似，瑞栓寧之

產品註冊證書已就新廠址獲

成功更新。本集團已開始瑞

栓寧之商業化，並開始與潛

在分銷商就省級經銷進行洽

談。

Asiunin is applied to simple anal fistula disease

without going through fistulotomy operation which

is traditionally used to cure anal fistula in western

medicine. Fistulotomy operation has a chance to

harm the sphincter muscle and cause relapses. It

is believed that the relapse rate when using Asiunin

for simple anal fistula is comparatively lower.

The Group strives to explore and capture

opportunities in emerging markets such as South

East Asia and in Africa, and to seek cooperation

which enables us to expand our business and

sales of tissue-engineering products with prominent

market potential.

Medical Technique — Cell Sheet-

Autologous Chondrocyte Implantation

(「CS-ACI」)

In addition to medical device products, the Group

also participates in research and development of

technological advanced medical techniques for

enhancing curative results.

At present, the sales and marketing team is

negotiating with various provincial agents in

finalising the implementation of a feasible business

model for CS-ACI. The role of the agents is to

connect and negotiate with hospitals for obtaining

their willingness to participate in the performance

of CS-ACI procedure. It may also involve the

collaboration of rehabilitation hospitals to ensure

post-surgical cartilage growth and recovery of

movement.

With the collaboration of AK Suzhou, we seek to

leverage Reshine’s CS-ACI technique, together

with AK Suzhou’s existing technique, to form

significant synergy for the development of CS-

ACI, and to market such technique to hospitals

in Huadong (Eastern region of China) and Dalian,

as an alternative treatment for knee prosthesis

replacement. AK Suzhou has signed an agreement

for providing CS-ACI cell-processing services

with The First Affiliated Hospital of Dalian Medical

University.

In addition to the above, the Group is also in the

process of conducting research and development

of other medical techniques.

瑞栓寧應用於治療簡單肛瘺

疾病，而無需進行西醫傳統

治療肛瘻的瘻管切開術。瘻

管切開術或會損害括約肌而

引起復發。使用瑞栓寧治療

簡單肛瘺之復發率被認為相

對較低。

本集團致力於在東南亞及非

洲等新興市場探索及把握商

機，並尋求合作，以使我們

能夠拓展我們的業務，並增

加具龐大市場潛力的組織工

程產品的銷量。

醫療技術

—自體軟骨細

胞膜片移植技術（「CS-

ACI」）

除醫療器械產品外，本集團

亦從事先進醫療技術之研究

及開發，以提高療效。

目前，銷售及營銷團隊正與

多名省級代理磋商落實執行

CS-ACI可行的商業模式。

代理的職責是與醫院進行聯

絡及商議，取得彼等同意

參與實施

CS-ACI手術之程

序。代理亦需與康復醫院合

作，以確保術後軟骨增長及

活動能力的康復。

於與奧凱蘇州合作後，我們

充分利用瑞盛之

CS-ACI技

術與奧凱蘇州之現有技術以

為發展

CS-ACI建立重大協

同效益，並在華東地區（中

國東部地區）以及大連的醫

院推廣應用此技術，作為膝

關節假體替換術的替代治療

方案。奧凱蘇州已與大連醫

科大學附屬第一醫院就提供

CS-ACI細胞加工服務簽署

協議。

除上述外，本集團亦正在研

發其他醫療技術。

B) CELLULAR AND STEM CELL RELATED B)細胞及幹細胞相關

OPERATIONS

With the guidance, knowledge, and know-hows

from Professor Zhanfeng Cui (「Prof. Cui」) of the

University of Oxford (「Oxford University」) who is

our main advisor, the Company has paved our

path and leveraged on his years of experience to

the development of cellular and stem cell therapy

related businesses.

In May 2015, the Company formed a special

vehicle company (「Special Vehicle」) with Prof.

Cui, in which Prof. Cui holds a minority interest, to

capture all future development of the Group's stem

cell related operations, including the development

of a stem cell clinical applications centre in Hong

Kong, China Stem Cell Clinical Applications Centre,

as the research and development base to support

the Group's stem cell initiatives in Hong Kong and

in the region, as well as concentrating in research

and development concerning immunotherapy;

neural regeneration; cardiovascular regeneration;

bone and connective tissue regeneration and

ocular regeneration.

The Group is building our China Stem Cell Clinical

Applications Centre at Phase 3 of Hong Kong

Science Park in Shatin. The 2,000 sq. metres

premise will be a world class facility that aims

to comply with EU EMA, US FDA and CFDA

standards for GMP requirements. Tenancy has

begun and the Group engaged a main consultant

company from the United Kingdom to participate

in and manage relevant processes ranging from

concept designs to detailed designs as well as

from construction to GMP validation. Renovation

of this GMP facility is expected to be completed

by 2016. The initial detailed facility design has

been submitted to Medical and Health Regulatory

Authority (MHRA) of the United Kingdom for

preliminary-checking on the compliance to EMA

GMP standard. MHRA has provided valuable

業務

憑藉我們的總顧問牛津大學

（「牛津大學」）崔佔峰院士

（「崔院士」）的指導、知識

及技能，以及藉著其多年經

驗，本公司已為發展細胞及

幹細胞治療相關業務做好準

備。

於二零一五年五月，本公司

與崔院士成立一間專項控股

公司（「專項控股公司」）（其

中崔院士持有少數股權），

以把握本集團幹細胞相關業

務的一切未來發展，包括在

香港建立一個幹細胞臨床應

用中心，即中國幹細胞臨床

應用中心，作為研發基地，

以支持本集團於香港及區內

的幹細胞計劃，以及專注於

有關免疫治療；神經再生；

心血管再生；骨骼及結締組

織再生以及眼部再生方面的

研發。

本集團正在位於沙田的香

港科學園三期成立中國幹

細胞臨床應用中心。該佔

地

2,000平方米的場所將成

為符合歐盟歐洲藥品管理局

(EMA)、美國食品與藥品管

理局

(FDA)及藥監總局標準

的具備良好生產規範

(GMP)

的世界級設施。有關租期已

開始，而本集團已委聘一家

英國的主要顧問公司參與及

管理自概念設計至詳細設計

的相關流程，以及建造至

GMP認證之過程。該

GMP

設施的裝修工程預計將於二

零一六年完工。該初步詳細

設施設計已遞交英國藥品

design alteration opinion so as to ensure that our

stem cell clinical application facility in Hong Kong

will comply with GMP clean-room standard for our

future cellular-therapy fabrication and development.

MHRA has also agreed to provide further advice on

our final detailed design once it is ready in 2016.

Similar pre-installation regulatory screening will also

be done for US FDA compliance after completion

of our EU EMA validation.

In early July 2015, the Special Vehicle established a

project company with a corporation founded by Dr.

Zhaohui Li to carry out adult human tissue storage

operations. This newly formed project company is

expected to collaborate with hospitals and clinics

for building adult human tissue storage facilities

in major cities in the PRC and aboard. It will also

utilise the Group's existing plant/facilities to build

regional supporting storage hubs to ensure that all

our future collected samples are covered by our

risk control and information and quality systems.

Adult human tissue storage is believed to have

vast opportunities as the market of regenerative

medicine expands.

和保健產品監管署

(MHRA)

進行初步審核，以核實是

否符合

EMA的

GMP標準。

MHRA已給予寶貴的設計改

進意見，以確保我們位於香

港的幹細胞臨床應用設施將

符合

GMP潔淨室的標準，

以用於我們日後細胞療法的

完善及發展。

MHRA亦已同

意於二零一六年我們的最終

詳細設計完成後提供進一步

意見。於完成歐盟

EMA核

證後，我們亦會就美國

FDA

規範進行安裝前監管審查程

序。

於二零一五年七月初，專項

控股公司與李朝暉博士創立

的一間企業合作成立一間項

目公司，以開展成人組織細

胞庫業務。新成立的項目公

司預期將與醫院和診所合

作，在中國主要城巿及海

外建造成人組織細胞庫之設

施，亦將利用本集團的現有

廠房╱設施，以建立區域存

儲支援樞紐，以確保未來所

有採集的樣本都被覆蓋於我

們的風險控制和信息及質量

系統之下。隨著再生醫學的

巿場不斷擴大，成人組織細

胞庫被視為擁有龐大的發展

機會。

By fostering our competitive edge and looking

to create value in cellular and stem cell related

industry, in September 2015, a subsidiary of the

Special Vehicle signed a joint-venture agreement

with Versitech Limited, the technology transfer

company and the commercial arm of the University

of Hong Kong (「Hong Kong University」), and

Professor Chi-Fung Chan, the Head of the

Department of Paediatrics & Adolescent Medicine

of Hong Kong University, to carry out cellular

therapy related business using various adult stem

cells and immune cells.

Elsewhere, the Group has taken proactive steps

in exploring and identifying business opportunities

in cellular and stem cell therapy application in

the PRC. Prof. Cui has brought to us acquisition

opportunities in two stem cell related companies

in the PRC, one focuses on clinical application

operations and the other one on pre-clinical

trial operations. The acquisition of the clinical

application operations of AK Suzhou was

completed in August 2015.

Prof. Cui also brought us the opportunity to

acquire 天津衛凱生物工程有限公司 (Tianjin Weikai

Bioeng Ltd., 「Tianjin Weikai」). This acquisition was

completed in April 2015. Tianjin Weikai focuses on

providing services and equipment for pre-clinical

trial applications of stem cell as well as contract

researches. Over the years, Tianjin Weikai has

stored up stem cell samples for research and

development, and human liver cells extracted

through its own unique techniques for contract

research organisation (「CRO」) testing particularly

on toxicity.

為增強我們的競爭優勢以及

在細胞及幹細胞相關行業創

造價值，於二零一五年九

月，專項控股公司的一間附

屬公司已與香港大學（「香

港大學」）屬下的技術轉讓

公司及商務機構港大科橋有

限公司及香港大學兒童及青

少年科學系主任陳志峰教授

訂立合作協議，以採用多種

成人幹細胞及免疫細胞開展

細胞治療相關業務。

此外，本集團已採取積極措

施，在中國探索及物色細胞

及幹細胞治療應用之商機。

崔院士已為我們帶來兩間與

幹細胞相關的中國公司的收

購機會，其中一間專注於臨

床應用業務，另一間專注於

臨床前試驗業務。收購奧凱

蘇州的臨床應用業務已於二

零一五年八月完成。

崔院士亦為我們帶來收購

天津衛凱生物工程有限公

司（「天津衛凱」）之機會，

該收購事項已於二零一五年

四月完成。天津衛凱專注於

為臨床前的幹細胞試驗應用

提供服務及設施，以及合同

式技術研究。多年以來，天

津衛凱已儲存用於研發之幹

細胞樣本，及透過其自有

獨特技術提取人體肝細胞

以供合同式技術研究組織

（「CRO」）測試（尤其是毒

性）。

C) COSMETICS AND HEALTHCARE C)美容及保健

During the period from 1 November 2015 to 本集團於二零一五年十一

31 January 2016, the Group sold high-end 月一日至二零一六年一月

cosmetic products to end users through mainly 三十一日期間，主要透過代

distributors. 理商銷售高檔美容展品給終

端消費者。

The Group will give attention to products with 本集團將專注於具有生長因

growth factors, collagen, and anti-aging elements. 子、膠原蛋白及抗衰老元素

We will utilise the derivatives resided during our 的產品。我們將利用在組織

production processes of the tissue-engineered 工程皮膚的生產過程中產生

skin in order to build up the product pipeline for 的衍生品建立美容產品生產

cosmetic products. We will also promote the 線。我們亦將推動抗衰老補

development of anti-aging supplement and other 充品及其他天然補充品的開

natural supplement products. 發。

The healthcare supplement business unit will be 健康補充品業務部門將由本

launched by the Group's subsidiary to develop, 集團附屬公司建立，以發展

and market anti-aging health supplement products. 及營銷抗衰老健康補充品。

D) MEDICAL EQUIPMENT AND OTHER D)醫療設備及其他服務

SERVICES

By utilising existing operations of the newly 透過營運於二零一五年四月

acquired Tianjin Weikai in late April 2015, the 下旬新收購的天津衛凱的現

Group offers CRO services of drug screening, drug 有業務，本集團提供臨床前

efficacy and toxicity assays in the pre-clinical drug 藥物開發服務中的藥物篩

development services. In addition to the traditional 選、藥物療效及毒性檢測的

cell culture, we have established the three

合同式技術研究服務。除了

dimensional (3D) cell culture drug screening and 傳統的細胞培養，根據三維

toxicity assays models based on the international 灌注細胞培養系統的國際先

advanced technology of 3D perfusion cell culture 進技術，我們已建立了三維

system. 細胞培養藥物篩選和毒性檢

測模型。

TissueFlex. and 3DFlo. are 3D perfusion cell

culture systems for pre-clinical applications which

enable the study of cellular behavior and function

in a more in-vivo-like environment that can provide

responses closely replicate human responses. The

3D perfusion cell culture system can reduce late

stage clinical trials failures by first identifying unsafe

drugs and through selection of the most efficacious

candidates earlier in the drug development

process. Tianjin Weikai is developing the second

generation of its 3D perfusion cell culture system,

the 3DFlo. so as to enhance additional automatic

control system.

BUSINESS OUTLOOK

The Group is continuously building sales and marketing

team for various product lines. A number of marketing

actions have been taken. Firstly, an ophthalmology

committee comprised of key opinion leaders and a training

institute have been formed so that ophthalmologists

can be trained to use our Acornea safely and effectively.

Secondly, we signed Distribution Agreements for Acornea

with sale distributors and realised sales revenue.

With additional products enlisted gradually moving into

clinical trials and regulatory approval stages, our product

pipeline will be further enhanced to meet diversified

clinical needs.

China Stem Cell Clinical Applications Centre at Hong

Kong Science Park is currently under design for which

we intend to bridge the long unresolved gap between

basic research scientists and clinicians by providing

various kinds of clinical graded cells and stem cells. By

positioning as a regional world class hub of its kind, we

aim to serve domestic clients as well as clients from

Southeast Asian countries and Taiwan. The Group is also

committed to build adult human tissue storage facilities to

tailor clients』 needs in various cities in the PRC and other

regions.

TissueFlex.及3DFlo.均為臨

床前應用的三維灌注細胞培

養系統，有助於研究細胞在

更類似體內環境（該環境下

可作出近似於人體反應的反

應）的表現及功能。該三維

灌注細胞培養系統透過預先

識別不安全藥物及在藥物開

發過程早期篩選療效最佳的

藥物，可以降低後期臨床試

驗時的失敗機率。天津衛凱

正在開發其第二代三維灌注

細胞培養系統

3DFlo.，以改

良附加的自動調節系統。

業務展望

本集團正繼續為多個產品線組建

銷售及營銷團隊，並已開展多項

營銷活動。首先，本集團已成立

由關鍵意見領袖組成的眼科專家

委員會及培訓機構，以培訓眼科

醫生安全有效地使用我們的艾欣

瞳。其次，本集團已與分銷商簽

訂艾欣瞳經銷合作協議並取得銷

售收益。

隨著更多的產品逐步進入臨床試

驗及註冊審批階段，我們的產品

線將進一步增強，滿足多元化的

臨床需求。

香港科學園的中國幹細胞臨床應

用中心目前正處於設計階段，我

們擬透過提供不同種類臨床級別

之細胞及幹細胞，以跨越基礎研

究科學家及臨床醫生之間長久以

來一直存在的鴻溝。為將該中心

定位為區內具世界級水準的幹細

胞臨床應用中心，我們致力服務

於本地以及東南亞國家及臺灣客

戶。本集團亦致力建設成人組織

細胞庫設施，滿足中國各城市及

其他地區客戶需求。

We are one of the sponsors for the Innovation and

Technology Fund programme (「ITF」) project 「Development

of a Human Mesenchymal Stem Cell (MSC)-based

Trilayered Osteochondral Graft for Osteoarthritis (OA)

Treatment」 (ITS/081/14FP) under the ITF, a Hong Kong

government sponsored program of research, to the

University of Hong Kong.

We will continue to seek collaboration opportunities with

leading institutions and scientists locally with the utilisation

of ITF.

The Group envisions itself to be the leading pioneer of

regenerative medicine in Asia and in the region. The

Group’s current production facilities in Xi』an, Shenzhen,

Tianjin and Suzhou in the PRC, are designated to the

development of both tissue engineering products and

techniques as well as cellular and stem cell therapy

related businesses.

The Group continues to look for viable fund raising

activities to finance its existing businesses and future and

potential developments.

FUTURE PROSPECT

The Group continues to strive for opportunity to widen

its business scope in the bio-medical area, as well as

strengthening and maintaining as one of the leading

pioneers in the medical and related industries. The

Group is negotiating with renowned scientists, clinicians,

hospitals and medical groups, and/or leading institutions

for long-term collaborations to seek new development in

the bio-medical and/or medical related industries.

The Chinese government has committed to provide

support towards hi-tech industries, including regenerative

medicine, a sub-division of the bio-medical industries.

We will continuously strive for more assistance from the

Chinese government to provide additional resources for

broadening our R&D coverage on regenerative medicine

spectrum. If we can access more support from local

government, for example high-technology subsidies

and relatively lower land cost, we may consider building

additional plants as well as research centres in other

suitable locations for our current and/or new products.

我們為創新及科技基金計劃（「創

科基金計劃」）（一項香港政府發起

的研究計劃）項目「研發用於治療

骨關節炎的充質幹細胞三層次組

織工程骨軟骨結構」（項目編號：

ITS/081/14FP）的贊助商之一，受

款方為香港大學。

我們將利用創科基金計劃，繼續

尋求與本地領先機構及科學家之

合作機會。

本集團展望是成為亞洲及區內的

再生醫學之先驅。本集團現時於

中國西安、深圳、天津及蘇州之

生產設備均為組織工程產品及技

術和細胞及幹細胞療法相關業務

發展提供支持。

本集團繼續物色可行的集資機

會，為其現有業務以及日後及潛

在發展提供資金。

未來前景

本集團將繼續爭取擴大其生物醫

學之業務範圍的機會，以及加強

和維持其在醫學及相關行業的領

先地位。本集團正與數位著名科

學家、臨床醫生、醫院、醫療組

織及╱或領先機構協商建立長期

合作關係，尋求生物醫學及╱或

醫藥相關產業的新發展。

中國政府一直致力對高新技術產

業提供支持，包括作為生物醫藥

產業分支的再生醫學。我們將繼

續爭取獲得中國政府的更多支

持，為擴大我們於再生醫學領域

之研發範圍提供額外資源。如我

們能獲地方政府更多的支持，例

如高科技術補貼及相對較低的地

價，我們或會考慮在其他合適選

址為我們現有及╱或新產品建設

新廠房以及研發中心。

As the Group continues to identify and invest in suitable

business opportunities, expand and improve in its

research and development capability, facilitate the

development of the existing business plan as well as

implementation of the sale and marketing strategy, the

Board may consider fund raising activities if viable fund

raising options, which are in the best interest of the Group

and the shareholders of the Company, are available.

FINANCIAL REVIEW

The Group’s revenue for the nine months period ended

31 January 2016 was approximately HK$17.38 million,

representing an increase of approximately HK$15.34

million, or 752%, compared to revenue of approximately

HK$2.04 million for last period. The overall increase

in revenue was primarily attributable to the increase in

revenue in both the segments of tissue engineering and

cosmetic and health products.

During the period under review, the Group incurred a

loss of approximately HK$139.11 million, as compared

to a loss of approximately HK$120.92 million for last

period. The loss was attributable to exchange loss of

approximately HK$31.81 million (2015: HK$1.10 million),

advertising expenses of approximately HK$16.31 million

(2015: 0.60 million) and research and development costs

of approximately HK$33.60 million (2015: HK$21.04

million), amongst others.

MATERIAL ACQUISITIONS/

DISPOSAL OF SUBSIDIARIES

AND ASSOCIATED COMPANIES

The Group had no material acquisitions/disposal of

subsidiaries and associated companies during the period.

本集團持續致力物色和投資於合

適商機、擴大和提高其研發能

力、促進發展現有業務計劃及

實施銷售及營銷策略，在此過程

中，董事會可能會在有符合本集

團及本公司股東最佳利益的可行

集資選擇時考慮進行集資活動。

財務回顧

本集團截至二零一六年一月

三十一日止九個月期間之收益約

為

17,380,000港元，較上一期間

收益約

2,040,000港元，增長約

15,340,000港元或

752%。收益整

體增長主要由於本集團組織工程

及美容及保健產品分部收益均有

所增加。

於回顧期間內，本集團產生虧損

約

139,110,000港元，而上一期

間虧損約為

120,920,000港元。

虧損歸因於（其中包括）滙兌虧

損約

31,810,000港元（二零一五

年：

1,100,000港元）、廣告開

支約

16,310,000港元（二零一五

年：

600,000港元）及研發成本約

33,600,000港元（二零一五年：

21,040,000港元）。

附屬公司及聯營公司

之重大收購╱出售事

項

期內本集團並無重大收購╱出售

附屬公司及聯營公司。

DIRECTORS』 AND CHIEF

EXECUTIVES』 INTERESTS AND

SHORT POSITIONS IN SHARES

AND UNDERLYING SHARES

As at 31 January 2016, the following Directors and chief

executives of the Company had or were deemed to

have interest or short positions in the shares, underlying

shares or debentures of the Company and its associated

corporations (within the meaning of Part XV of the

Securities and Futures Ordinance (Chapter 571 of the

Laws of Hong Kong) (the 「SFO」)) (i) which were required

to be notified to the Company and the Stock Exchange

pursuant to Divisions 7 and 8 of Part XV of the SFO

(including interests or short positions which they were

taken or deemed to have under such provisions of the

SFO); or (ii) which were required, pursuant to Section

352 of the SFO, to be entered in the register referred to

therein; or (iii) which were, pursuant to Rules 5.46 to 5.67

of the GEM Listing Rules related to securities transactions

by the Directors to be notified to the Company and the

Stock Exchange:

LONG POSITIONS

Interests in the shares and underlying shares of

the Company

董事及最高行政人員

於股份及相關股份之

權益及淡倉

於二零一六年一月三十一日，下

列董事及本公司最高行政人員於

本公司及其相聯法團（定義見香

港法例第

571章證券及期貨條例

（「證券及期貨條例」）第

XV部）之

股份、相關股份或債券中，擁有

或被視作擁有

(i)根據證券及期貨條

例第

XV部第

7及

8分部須知會本

公司及聯交所之權益或淡倉（包括

彼等根據證券及期貨條例有關條

文被當作或視作擁有之權益或淡

倉）；或

(ii)根據證券及期貨條例第

352條須記入該條所述登記冊之權

益或淡倉；或

(iii)根據創業板上市

規則第

5.46至

5.67條有關董事進

行證券交易之規定須知會本公司

及聯交所之權益或淡倉如下：

好倉

於本公司股份及相關股份之

權益

Aggregate long Approximate

position in the percentage of

Name of Directors/ shares and the issued

chief executives Capacity underlying shares share capital

於股份及已發行

相關股份之股本概約

董事

╱最高行政人員姓名身份好倉總計百分比

Dai Yumin (Note 1) Held by controlled 4,068,100,319 23.12%

戴昱敏（附註

1）

corporation

由受控法團持有

Held by his spouse 11,905,000 0.07%

由其配偶持有

Beneficial owner 61,685,000 0.35%

實益擁有人

Wang Yurong (Note 2) Held by controlled 1,200,000,000 6.82%

王玉榮（附註

2）

corporation

由受控法團持有

Beneficial owner 17,500,000 0.10%

實益擁有人

Aggregate long Approximate

position in the percentage of

Name of Directors/ shares and the issued

chief executives Capacity underlying shares share capital

於股份及已發行

相關股份之股本概約

董事

╱最高行政人員姓名身份好倉總計百分比

Cao Fushun (Note 3) Held by controlled 691,115,000 3.93%

曹福順（附註

3）

corporation

由受控法團持有

Beneficial owner 27,730,000 0.16%

實益擁有人

Wong Sai Hung Interests held jointly 30,000,000 0.17%

(Note 4) with another person

黃世雄（附註

4）與其他人士共同

持有的權益

Beneficial owner 7,560,000 0.04%

實益擁有人

Deng Shaoping Beneficial owner 5,780,000 0.03%

(Note 5)實益擁有人

鄧紹平（附註

5）

Yang Zhengguo Beneficial owner 6,300,000 0.04%

(Note 5)實益擁有人

楊正國（附註

5）

Wang Jianjun (Note 5) Beneficial owner 5,780,000 0.03%

王建軍（附註

5）實益擁有人

Lui Tin Nang (Note 6) Beneficial owner 2,100,000 0.01%

呂天能（附註

6）實益擁有人

Pang Chung Fai Beneficial owner 2,010,000 0.01%

Benny (Note 6)實益擁有人

彭中輝先生（附註

6）

Chan Bing Woon Beneficial owner 1,930,000 0.01%

(Note 6)實益擁有人

陳炳煥（附註

6）

Wang Hui (Note 6) Beneficial owner 1,750,000 0.01%

王輝（附註

6）實益擁有人

Shao Zhengkang Beneficial owner 12,530,000 0.07%

(Note 7)實益擁有人

邵政康（附註

7）

Tam Man Kin (Note 8) Beneficial owner 6,130,000 0.03%

譚文健（附註

8）實益擁有人

Notes: 附註：

1. All Favour Holdings Limited (「All Favour」) is beneficially 1.全輝控股有限公司（「全輝」）分

owned as to (i) 40% by Nat-Ace Wood Industry Ltd. (「Nat-

Ace Wood Industry」) and 20% by Honour Top Holdings

Limited which are both ultimately wholly owned by Mr.

Dai Yumin (「Mr. Dai」), an executive Director; and (ii) 40%

by Mr. Hu Yonggang (「Mr. Hu」). On 5 March 2015, the

Company granted to All Favour an option (「Option」)

which carries a right to subscribe for up to 360,000,000

new shares of the Company at the initial exercise price of

HK$0.25 per share (subject to adjustment) upon exercise

of such Option by All Favour. Moreover, All Favour has

been the beneficial owner of 3,708,100,319 shares of

the Company. Assuming exercise of the Option in full, All

Favour shall hold an aggregate of 4,068,100,319 shares

of the Company.

Ms. Deng Shufen (「Ms. Deng」), the spouse of Mr. Dai has

beneficial interests in 11,905,000 shares of the Company

as at 31 January 2016. By virture of the SFO, Mr. Dai

is deemed to be interested in 11,905,000 shares of the

Company held by Ms. Deng as at 31 January 2016.

By virtue of the SFO, Mr. Dai, Ms. Deng, Mr. Hu and Nat-

Ace Wood Industry are deemed to be interested in an

aggregate of 4,068,100,319 shares of the Company in

which All Favour is interested.

On 16 September 2015, Mr. Dai was granted 17,500,000

share options (the 「Share Options」) by the Company under

the share option scheme of the Company adopted on 14

September 2011 (the 「Share Option Scheme」) entitling

him to subscribe for 17,500,000 shares of the Company

at the exercise price of HK$0.45 per share (「Exercise

Price」), subject to the terms and conditions of the Share

Option Scheme. Moreover, Mr. Dai personally holds

44,185,000 shares of the Company. Assuming exercise of

the Share Options in full, Mr. Dai shall hold an aggregate of

61,685,000 shares of the Company as beneficial owner.

別由

(i)邦強木業有限公司（「邦

強木業」）實益擁有

40%及

Honour Top Holdings Limited

實益擁有

20%，而彼等均由執

行董事戴昱敏先生（「戴先生」）

最終全資擁有；及

(ii)胡永剛先

生（「胡先生」）實益擁有

40%。

於二零一五年三月五日，本公

司向全輝授出購股權（「購股

權」），該購股權將附帶權利於

全輝行使相關購股權時按初步

行使價每股股份

0.25港元（可

予調整）認購最多

360,000,000

股本公司新股份。此外，全輝

為

3,708,100,319股本公司股

份之實益擁有人。假設購股權

獲悉數行使，全輝將持有合共

4,068,100,319股本公司股份。

鄧淑芬女士（「鄧女士」），為

戴先生之配偶，於二零一六年

一月三十一日於

11,905,000股

本公司股份中實益擁有權益。

根據證券及期貨條例，戴先生

被視為於鄧女士於二零一六年

一月三十一日在本公司持有的

11,905,000股股份中擁有權益。

根據證券及期貨條例，戴先

生、鄧女士、胡先生及邦強木

業被視為於全輝擁有權益的合

共

4,068,100,319股本公司股份

中擁有權益。

於二零一五年九月十六日，戴

先生獲本公司根據本公司於二

零一一年九月十四日採納之購

股權計劃（「購股權計劃」）授予

17,500,000份股份購股權（「股

份購股權」），賦予其權利可按

每股

0.45港元之行使價（「行使

價」）認購

17,500,000股本公司

股份，惟須遵守購股權計劃之

條款及條件。此外，戴先生個

人持有

44,185,000股本公司股

份。假設股份購股權獲悉數行

使，戴先生將作為實益擁有人

持有合共

61,685,000股本公司

股份。

By virtue of the SFO, Mr. Dai and Ms. Deng, together with 根據證券及期貨條例，於二零

their deemed interests in All Favour, are deemed to be 一六年一月三十一日，連同彼

interested in an aggregate of 4,141,690,319 shares of the 等被視為於全輝擁有之權益，

Company as at 31 January 2016. 戴先生及鄧女士被視為於合共

4,141,690,319股本公司股份中

擁有權益。

The Company was informed by All Favour that it has 本公司獲全輝告知，其已將其

pledged its interests in 1,301,320,319 shares of the 於

1,301,320,319股本公司股份

Company in favour of Optimus Prime Management Ltd. 中的權益抵押予

Optimus Prime

Management Ltd.。

2. China Sheng Rong Investment Holding Limited (「Sheng 2.中國晟融投資控股有限公司

Rong」) is beneficially owned as to (i) 51% by Mr. Guan （「晟融」）分別由

(i)關國亮先生

Baker Guo Liang (「Mr. Guan」); and (ii) 49% by Ms. Wang （「關先生」）實益擁有

51%；及

Yurong (「Ms. Wang」), an executive Director. Mr. Guan (ii)執行董事王玉榮女士（「王

and Ms. Wang are spouses. Sheng Rong has been the 女士」）實益擁有

49%。關先

beneficial owner of 1,200,000,000 shares of the Company. 生及王女士為配偶。晟融為

1,200,000,000股本公司股份之

實益擁有人。

On 16 September 2015, Ms. Wang was granted 於二零一五年九月十六日，王

17,500,000 Share Options by the Company under the 女士獲本公司根據購股權計劃

Share Option Scheme entitling her to subscribe for 授予

17,500,000份股份購股

17,500,000 shares of the Company at the Exercise Price, 權，賦予其權利可按行使價認

subject to the terms and conditions of the Share Option 購

17,500,000股本公司股份，

Scheme. Assuming exercise of the Share Options in 惟須遵守購股權計劃之條款及

full, Ms. Wang shall hold the 17,500,000 shares of the 條件。假設股份購股權獲悉數

Company as beneficial owner. 行使，王女士將作為實益擁有

人持有

17,500,000股本公司股

份。

By virtue of the SFO, Ms. Wang and Mr. Guan, together 根據證券及期貨條例，於二零

with their deemed interest in Sheng Rong, are deemed to 一六年一月三十一日，連同彼

be interested in an aggregate of 1,217,500,000 shares of 等被視為於晟融擁有之權益，

the Company as at 31 January 2016. 王女士及關先生被視為於合共

1,217,500,000股本公司股份中

擁有權益。

The Company was informed by Sheng Rong that it has 本公司獲晟融告知，其已將

pledged its interests in 1,200,000,000 shares of the 其於

1,200,000,000股本公司

Company in favour of Dundee Greentech Limited.股份中的權益抵押予

Dundee

Greentech Limited。

3. Gold Fortune Profits Limited (「Gold Fortune」) is wholly 3. Gold Fortune Profits Limitedowned by Mr. Cao Fushun (「Mr. Cao」), a non-executive （「Gold Fortune」）由非執行董

Director. Gold Fortune has been the beneficial owner of 事曹福順先生（「曹先生」）全

691,115,000 shares of the Company as at 31 January 資擁有。於二零一六年一月

2016. 三十一日，

Gold Fortune為

691,115,000股本公司股份之實

益擁有人。

Moreover, Mr. Cao personally holds 22,220,000 shares of 此外，曹先生個人持有

the Company. 22,220,000股本公司股份。

On 16 September 2015, Mr. Cao was granted 5,510,000 於二零一五年九月十六日，曹

Share Options by the Company under the Share Option 先生獲本公司根據購股權計

Scheme entitling him to subscribe for 5,510,000 shares of 劃授予

5,510,000份股份購股

the Company at the Exercise Price, subject to the terms 權，賦予其權利可按行使價認

and conditions of the Share Option Scheme. Assuming 購

5,510,000股本公司股份，惟

exercise of the Share Options in full, by virtue of the SFO, 須遵守購股權計劃之條款及條

Mr. Cao shall hold an aggregate of 27,730,000 shares 件。於二零一六年一月三十一

of the Company as beneficial owner, and together with 日，假設股份購股權獲悉數行

his deemed interests in Gold Fortune, is deemed to be 使，根據證券及期貨條例，曹

interested in an aggregate of 718,845,000 shares of the 先生將作為實益擁有人持有合

Company as at 31 January 2016. 共

27,730,000股本公司股份，

連同其被視為於

Gold Fortune

擁有之權益，曹先生被視為於

合共

718,845,000股本公司股份

中擁有權益。

4. Mr. Wong Sai Hung (「Mr. Wong」) is an executive Director 4.黃世雄先生（「黃先生」）為執行

and the Chairman of the Board. Mr. Wong’s interests 董事兼董事會主席。黃先生的

are held jointly with his spouse. By virtue of the SFO, Mr. 權益與其配偶共同持有。根據

Wong and his spouse are deemed to be interested in 證券及期貨條例，黃先生及其

30,000,000 shares of the Company. 配偶被視為於

30,000,000股本

公司股份中擁有權益。

On 16 September 2015, Mr. Wong was granted 7,560,000 於二零一五年九月十六日，黃

Share Options by the Company under the Share Option 先生獲本公司根據購股權計

Scheme entitling him to subscribe for 7,560,000 shares of 劃授予

7,560,000份股份購股

the Company at the Exercise Price, subject to the terms 權，賦予其權利可按行使價認

and conditions of the Share Option Scheme. Assuming 購

7,560,000股本公司股份，

exercise of the Share Options in full, Mr. Wong shall hold 惟須遵守購股權計劃之條款及

the 7,560,000 shares of the Company as beneficial owner. 條件。假設股份購股權獲悉數

By virtue of the SFO, Mr. Wong and his spouse, together 行使，黃先生將作為實益擁有

with their deemed interest in the shares held jointly, shall 人持有

7,560,000股本公司股

be deemed to be interested in an aggregate of 37,560,000 份。根據證券及期貨條例，於

shares of the Company as at 31 January 2016. 二零一六年一月三十一日，連

同其被視為於與其配偶共同持

有之股份中擁有之權益，黃先

生及其配偶應被視為於合共

37,560,000股本公司股份中擁

有權益。

5. On 16 September 2015, Professor Deng Shaoping 5.於二零一五年九月十六日，非

(「Prof. Deng」), Mr. Yang Zhengguo (「Mr. Yang」) and Mr. 執行董事鄧紹平教授（「鄧教

Wang Jianjun (「Mr. Wang」), non-executive Directors, 授」）、楊正國先生（「楊先生」）

were granted 5,780,000, 6,300,000 and 5,780,000 及王建軍先生（「王先生」）分別

Share Options respectively by the Company under the 獲本公司根據購股權計劃授予

Share Option Scheme entitling each of them to subscribe 5,780,000份、

6,300,000份及

for 5,780,000, 6,300,000 and 5,780,000 shares of the 5,780,000份股份購股權，賦予

Company respectively at the Exercise Price, subject to 彼等各自權利分別可按行使價

the terms and conditions of the Share Option Scheme. 認購

5,780,000股、

6,300,000Assuming exercise of the Share Options in full, Prof. Deng, 股及

5,780,000股本公司股份，

Mr. Yang and Mr. Wang shall hold 5,780,000, 6,300,000 惟須遵守購股權計劃之條款及

and 5,780,000 shares of the Company respectively as 條件。假設股份購股權獲悉數

beneficial owners. By virtue of the SFO, Prof. Deng, Mr. 行使，鄧教授、楊先生及王先

Yang and Mr. Wang shall be deemed to be respectively 生分別將作為實益擁有人持有

interested in 5,780,000, 6,300,000 and 5,780,000 shares 5,780,000股、

6,300,000股及

of the Company as at 31 January 2016. 5,780,000股本公司股份。根據

證券及期貨條例，於二零一六

年一月三十一日，鄧教授、楊

先生及王先生應被視為分別於

5,780,000股、

6,300,000股及

5,780,000股本公司股份中擁有

權益。

6. On 16 September 2015, Mr. Lui Tin Nang (「Mr. Lui」), 6.於二零一五年九月十六日，獨

Mr. Pang Chung Fai Benny (「Mr. Pang」), Mr. Chan Bing 立非執行董事呂天能先生（「呂

Woon (「Mr. Chan」) and Mr. Wang Hui (「Mr. H Wang」), 先生」）、彭中輝先生（「彭先

independent non-executive Directors, were granted 生」）、陳炳煥先生（「陳先生」）

2,100,000, 2,010,000, 1,930,000 and 1,750,000 Share 及王輝先生（「王輝先生」）分別

Options respectively by the Company under the Share 獲本公司根據購股權計劃授予

Option Scheme entitling each of them to subscribe for 2,100,000份、

2,010,000份、

2,100,000, 2,010,000, 1,930,000 and 1,750,000 shares 1,930,000份及

1,750,000份股

of the Company respectively at the Exercise Price, subject 份購股權，賦予彼等各自權利

to the terms and conditions of the Share Option Scheme. 分別可按行使價認購

2,100,000Assuming exercise of the Share Options in full, Mr. Lui, 股、

2,010,000股、

1,930,000Mr. Pang, Mr. Chan and Mr. H Wang shall hold 2,100,000, 股及

1,750,000股本公司股份，2,010,000, 1,930,000 and 1,750,000 shares of the 惟須遵守購股權計劃之條款及

Company respectively as beneficial owners. By virtue of 條件。假設股份購股權獲悉數

the SFO, Mr. Lui, Mr. Pang, Mr. Chan and Mr. H Wang 行使，呂先生、彭先生、陳先

shall be deemed to be respectively interested in 2,100,000, 生及王輝先生分別將作為實

2,010,000, 1,930,000 and 1,750,000 shares of the 益擁有人持有

2,100,000股、

Company as at 31 January 2016. 2,010,000股、

1,930,000股及

1,750,000股本公司股份。根據

證券及期貨條例，於二零一六

年一月三十一日，呂先生、彭

先生、陳先生及王輝先生應

被視為分別於

2,100,000股、

2,010,000股、

1,930,000股及

1,750,000股本公司股份中擁有

權益。

7.

On 16 September 2015, Dr. Shao Zhengkang (「Dr. Shao」),

chief executive officer of the Company, was granted

12,030,000 Share Options by the Company under the

Share Option Scheme entitling him to subscribe for

12,030,000 shares of the Company at the Exercise Price,

subject to the terms and conditions of the Share Option

Scheme. Moreover, Dr. Shao personally holds 500,000

shares of the Company. Assuming exercise of the Share

Options in full, Dr. Shao shall hold an aggregated of

12,530,000 shares of the Company as beneficial owner.

By virtue of the SFO, Dr. Shao shall be deemed to be

interested in an aggregate of 12,530,000 shares of the

Company as at 31 January 2016.

8.

On 16 September 2015, Mr. Tam Man Kin (「Mr. Tam」),

chief financial officer of the Company, was granted

6,130,000 Share Options by the Company under the

Share Option Scheme entitling him to subscribe for

6,130,000 shares of the Company at the Exercise Price,

subject to the terms and conditions of the Share Option

Scheme. Assuming exercise of the Share Options in full,

Mr. Tam shall hold the 6,130,000 shares of the Company

as beneficial owner. By virtue of the SFO, Mr. Tam shall

be deemed to be interested in 6,130,000 shares of the

Company as at 31 January 2016.

Save as disclosed above, as at 31 January 2016, none

of the Directors nor the chief executives of the Company

had or was deemed to have any interests or short

positions in the shares, underlying shares or debentures

of the Company and its associated corporations (within

the meaning of Part XV of the SFO) (i) which were

required to be notified to the Company and the Stock

Exchange pursuant to Divisions 7 and 8 of Part XV of the

SFO (including interests or short positions which they

were taken or deemed to have under such provisions of

the SFO); or (ii) which were required, pursuant to Section

352 of the SFO, to be entered in the register referred to

therein; or (iii) which were, pursuant to Rules 5.46 to 5.67

of the GEM Listing Rules relating to securities transactions

by Directors to be notified to the Company and the Stock

Exchange.

7.

於二零一五年九月十六日，本

公司之行政總裁邵政康博士

（「邵博士」）獲本公司根據購股

權計劃授予

12,030,000份股份

購股權，賦予其權利可按行使

價認購

12,030,000股本公司股

份，惟須遵守購股權計劃之條

款及條件。此外，邵博士個人

持有

500,000股本公司股份。

假設股份購股權獲悉數行使，

邵博士將作為實益擁有人持有

12,530,000股本公司股份。

根據證券及期貨條例，於二零

一六年一月三十一日，邵博士

應被視為於合共

12,530,000股

本公司股份中擁有權益。

8.

於二零一五年九月十六日，本

公司之首席財務官譚文健先生

（「譚先生」）獲本公司根據購股

權計劃授予

6,130,000份股份購

股權，賦予其權利可按行使價

認購

6,130,000股本公司股份，

惟須遵守購股權計劃之條款及

條件。假設股份購股權獲悉數

行使，譚先生將作為實益擁有

人持有

6,130,000股本公司股

份。根據證券及期貨條例，於

二零一六年一月三十一日，譚

先生應被視為於

6,130,000股本

公司股份中擁有權益。

除上文所披露者外，於二零一六

年一月三十一日，概無董事或本

公司最高行政人員於本公司及其

相聯法團（定義見證券及期貨條例

第

XV部）之股份、相關股份或債

券中，擁有或視作擁有

(i)根據證券

及期貨條例第

XV部第

7及

8分部

須知會本公司及聯交所之權益或

淡倉（包括彼等根據證券及期貨條

例有關條文被當作或視作擁有之

權益或淡倉）；或

(ii)根據證券及期

貨條例第

352條須記入該條所述登

記冊之權益或淡倉；或

(iii)根據創

業板上市規則第

5.46至

5.67條有

關董事進行證券交易之規定須知

會本公司及聯交所之權益或淡倉。

SUBSTANTIAL SHAREHOLDERS』

AND OTHER PERSONS』

INTERESTS IN SHARES AND

UNDERLYING SHARES

So far as known to the Directors, as at 31 January 2016,

the following parties (not being the Directors or chief

executives of the Company) had, or were deemed to

have, interests or short positions in the shares, underlying

shares or debentures of the Company (i) which would fall

to be disclosed to the Company and the Stock Exchange

under the provisions of Divisions 2 and 3 of Part XV of

the SFO; or (ii) which were required, pursuant to Section

336 of the SFO, to be entered in the register referred to

therein:

LONG POSITIONS

Interests in the shares and underlying shares of

the Company

主要股東及其他人士

於股份及相關股份之

權益

據董事所知，於二零一六年一月

三十一日，下列人士（非董事或本

公司最高行政人員）於本公司股

份、相關股份或債券中，擁有或

被視作擁有

(i)根據證券及期貨條例

第

XV部第

2及

3分部之條文須向

本公司及聯交所披露之權益或淡

倉；或

(ii)根據證券及期貨條例第

336條須記入該條所述登記冊內之

權益或淡倉：

好倉

於本公司股份及相關股份之

權益

Aggregate long Approximate

position in the percentage

Name of shares and of the issued

Shareholders Capacity underlying shares share capital

於股份及相關佔已發行股本

股東姓名

╱名稱身份股份之好倉總計概約百分比

Nat-Ace Wood Industry Held by controlled 4,068,100,319 23.12%

(Note 1 above) corporation

邦強木業（上文附註

1）由受控法團持有

Hu Yonggang Held by controlled 4,068,100,319 23.12%

(Note 1 above) corporation

胡永剛（上文附註

1）由受控法團持有

All Favour Beneficial owner 4,068,100,319 23.12%

(Note 1 above)實益擁有人

全輝（上文附註

1）

Deng Shufen Held by her spouse 4,068,100,319 23.12%

(Note 1 above) through controlled

鄧淑芬（上文附註

1）

corporation

由其配偶透過

受控法團持有

Beneficial owner 11,905,000 0.07%

實益擁有人

Held by her spouse 61,685,000 0.35%

由其配偶持有

Aggregate long Approximate

position in the percentage

Name of shares and of the issued

Shareholders Capacity underlying shares share capital

於股份及相關佔已發行股本

股東姓名

╱名稱身份股份之好倉總計概約百分比

China Orient Asset Held by controlled 384,000,000 2.18%

Management corporation

Corporation由受控法團持有

(Note 9 below) Person having a security 1,301,320,319 7.40%

中國東方資產管理公司

interest in Shares（下文附註

9）

though controlled

corporation

透過受控法團

對股份持有保證

權益之人士

Guan Baker Guo Liang Held by controlled 1,200,000,000 6.82%

(Note 2 above) corporation

關國亮（上文附註

2）由受控法團持有

Held by his spouse 17,500,000 0.10%

由其配偶持有

Sheng Rong Beneficial owner 1,200,000,000 6.82%

(Note 2 above)實益擁有人

晟融（上文附註

2）

Dundee Greentech Person having a security 1,500,000,000 8.53%

Limited interest in shares

(Note 10 below)對股份持有保證

（下文附註

10）權益之人士

Liu Hailong Person having a security 1,500,000,000 8.53%

(Note 10 below) interest in shares

劉海龍（下文附註

10）對股份持有保證

權益之人士

Sheng Yuan Global Trustee 1,000,000,000 5.68%

High Growth受託人

Industries Fund

Series SPC

(Note 11 below)

盛源全球高增長

行業系列基金

獨立投資組合公司

（下文附註

11）

Notes:

9.

Based on Forms 2 dated 9 September 2015, 20 May

2015 and 22 April 2015 filed by China Orient Asset

Management Corporation (「COAMC」), Optimus Prime

Management Ltd. (「Optimus」) has a security interest

in 1,301,320,319 shares of the Company and China

Orient Asset Management (International) Holding Limited

(「COAMI」) has an interest in 384,000,000 shares of the

Company. Optimus is wholly owned by COAMI. COAMI

is owned as to (i) 50% by Wise Leader Assets Ltd. (「Wise

Leader」) which is wholly owned by Dong Yin Development

(Holdings) Limited (「Dong Yin」); and (ii) 50% by Dong Yin

which is wholly owned by COAMC. By virtue of the SFO,

Dong Yin, Wise Leader and COAMC are deemed to be

interested in 384,000,000 shares of the Company held by

COAMI, and COAMI, Dong Yin, Wise Leader and COAMC

are deemed to be interested in 1,301,320,319 shares of

the Company held by Optimus as security interest.

10.

Based on the Form 2 and Form 1 both filed on 30 March

2015 by Dundee Greentech Limited (「Dundee Greentech」)

and Mr. Liu Hailong (「Mr. Liu」) respectively, each of

Dundee Greentech and Mr. Liu has a security interest in

1,500,000,000 shares of the Company.

11.

Based on the Form 2 filed on 4 August 2015 by Sheng

Yuan Global High Growth Industries Fund Series SPC

(「Sheng Yuan GHGI Fund」), Sheng Yuan GHGI Fund holds

1,000,000,000 shares of the Company as a trustee.

Save as disclosed above, as at 31 January 2016, the

Directors are not aware that there is any other party

(other than the Directors and the chief executives of the

Company) who had, or was deemed to have, interests

or short positions in the shares, underlying shares and

debentures of the Company (i) which would fall to be

disclosed to the Company and Stock Exchange under

the provisions of Divisions 2 and 3 of Part XV of the SFO;

or (ii) which were required, pursuant to section 336 of the

SFO, to be entered in the register referred to therein.

附註：

9.

根據中國東方資產管理公司

（「東方資產」）提交的日期為二

零一五年九月九日、二零一五

年五月二十日及二零一五年四

月二十二日的表格

2，Optimus

Prime Management Ltd.

（「Optimus」）於

1,301,320,319

股本公司股份中持有保證權益

且中國東方資產管理（國際）控

股有限公司（「東方國際」）於

384,000,000股本公司股份中擁

有權益。

Optimus由東方國際

全資擁有。東方國際分別由

(i)

Wise Leader Assets Ltd.（「Wise

Leader」，由東銀發展（控股）

有限公司（「東銀」）全資擁有）

擁有

50%；及

(ii)東銀（由東方

資產全資擁有）擁有

50%。根

據證券及期貨條例，東銀、

Wise Leader及東方資產被視為

於東方國際持有的

384,000,000

股本公司股份中擁有權益，而

東方國際、東銀、

Wise Leader

及東方資產被視為於

Optimus

持作保證權益的

1,301,320,319

股本公司股份中擁有權益。

10.

根據分別由

Dundee Greentech

Limited（「Dundee Greentech」）

及劉海龍先生（「劉先生」）提

交的日期為二零一五年三月

三十日的表格

2及表格

1，

Dundee Greentech及劉先生各

於

1,500,000,000股本公司股份

中擁有保證權益。

11.

根據盛源全球高增長行業系列

基金獨立投資組合公司（「盛源

全球高增長行業系列基金」）提

交的日期為二零一五年八月四

日的表格

2，盛源全球高增長

行業系列基金作為受託人持有

1,000,000,000股本公司股份。

除上文所披露者外，於二零一六

年一月三十一日，董事概不知悉

任何其他人士（董事及本公司最高

行政人員除外）於本公司股份、相

關股份及債券中，擁有或被視作

擁有

(i)根據證券及期貨條例第

XV

部第

2及

3分部之條文須向本公司

及聯交所披露之權益或淡倉；或

(ii)

根據證券及期貨條例第

336條須記

入該條所述登記冊內之權益或淡

倉。

DIRECTOR』S RIGHT TO ACQUIRE

SHARES OR DEBENTURES

Save as disclosed under the heading 「DIRECTORS』

AND CHIEF EXECUTIVES』 INTERESTS AND SHORT

POSITIONS IN SHARES AND UNDERLYING SHARES」

above, at no time during the reporting period were rights

to acquire benefits by means of the acquisition of shares

in or debentures of the Company or of any other body

corporate granted to any directors, their respective

spouse or children under 18 years of age, or were any

such rights exercised by them; or was the Company, its

holding company or any of its subsidiaries a party to any

arrangements to enable the Directors, their respective

spouse or children under 18 years of age to acquire such

rights in the Company or any other body corporate as at

31 January 2016.

COMPETING INTERESTS

None of the Directors or the substantial shareholders of

the Company, or any of their respective close associates

(as defined under the GEM Listing Rules) had any interest

in a business that competes or may compete with the

business of the Group during the nine months ended

31 January 2016.

AUDIT COMMITTEE

The audit committee of the Company (the 「Audit

Committee」) has four members, comprising all

independent non-executive Directors, namely Mr. Lui Tin

Nang (the chairman of the Audit Committee), Mr. Pang

Chung Fai Benny, Mr. Chan Bing Woon and Mr. Wang

Hui. The Company’s unaudited consolidated results for

the nine months ended 31 January 2016 have been

reviewed by the Audit Committee.

董事收購股份或債權

證之權利

除上文「董事及最高行政人員於股

份及相關股份之權益及淡倉」一節

所披露者外，於報告期內任何時

間，概無任何董事或彼等各自之

配偶或未滿

18歲之子女獲授或行

使任何可透過購買本公司或任何

其他法人團體之股份或債權證而

獲益之權利；或於二零一六年一

月三十一日，本公司、其控股公

司或其任何附屬公司並無訂立任

何安排，致使董事、彼等各自之

配偶或未滿

18歲之子女獲得本公

司或任何其他法人團體之該等權

利。

競爭權益

截至二零一六年一月三十一日止

九個月，概無任何董事或本公司

主要股東或任何彼等各自之緊密

聯繫人（定義見創業板上市規則）

於與本集團業務構成競爭或可能

構成競爭之業務中擁有任何權益。

審核委員會

本公司之審核委員會（「審核委員

會」）有四位成員，包括所有獨立

非執行董事，即呂天能先生（審核

委員會主席）、彭中輝先生、陳炳

煥先生及王輝先生。審核委員會

已審閱本公司截至二零一六年一

月三十一日止九個月之未經審核

綜合業續。

PURCHASE, SALE OR

REDEMPTION OF SECURITIES

During the nine months ended 31 January 2016, neither

the Company nor any of its subsidiaries purchased,

redeemed or sold any of the Company’s listed securities.

By Order of the Board of

China Regenerative Medicine International Limited

Dai Yumin

Executive Director

Hong Kong, 15 March 2016

As at the date of this report, the executive Directors are

Mr. Dai Yumin, Ms. Wang Yurong and Mr. Wong Sai

Hung; the non-executive Directors are Professor Deng

Shaoping, Mr. Cao Fushun, Mr. Yang Zhengguo and

Mr. Wang Jianjun; and the independent non-executive

Directors are Mr. Lui Tin Nang, Mr. Pang Chung Fai

Benny, Mr. Chan Bing Woon, SBS,JP and Mr. Wang Hui.

This report will remain on the 「Latest Company

Announcements」 page of the GEM website at

www.hkgem.com for at least seven days from the date

of the publication and will be published on the website of

the Company at www.crmi.hk.

購買、出售或贖回

證券

截至二零一六年一月三十一日止

九個月，本公司或其任何附屬公

司概無購買、贖回或出售本公司

任何上市證券。

承董事會命

中國再生醫學國際有限公司

執行董事

戴昱敏

香港，二零一六年三月十五日

於本報告日期，執行董事為戴昱

敏先生、王玉榮女士及黃世雄先

生；非執行董事為鄧紹平教授、

曹福順先生、楊正國先生及王建

軍先生；獨立非執行董事為呂天

能先生、彭中輝先生、陳炳煥先

生（銀紫荊星章、太平紳士）及王輝先

生。

本報告將由刊發日期起計至少保留

七日於創業板網站

www.hkgem.com

之「最新公司公告」一頁及於本公

司之網站

www.crmi.hk內登載。

China Regenerative Medicine

International Limited

中國再生醫學國際有限公司

www.crmi.hkChina Regenerative Medicine

International Limited

中國再生醫學國際有限公司

www.crmi.hk

　 中財網